Navigation Links
Taiho Pharmaceutical présente une demande d'homologation pour la fabrication et la commercialisation du nouvel agent antitumoral TAS-102
Date:2/26/2013

TOKYO, 27 février 2013 /PRNewswire/ -- Taiho Pharmaceutical Co., Ltd. a annoncé le 27 février avoir présenté le 26 février une demande d'homologation pour la fabrication et la commercialisation du nouvel agent antitumoral nucléoside administré par voie orale, le TAS-102 (mélange de Trifluorothymidine [FTD] et de tipiracil hydrochloride[TPI]), auprès du Ministère japonais de la Santé publique et du Travail. Taiho Pharmaceutical cherche à obtenir l'homologation pour le TAS-102 de l'indication contre le cancer colorectal récurrent à un stade avancé, non résécable.

La demande d'homologation se base sur les résultats de l'essai clinique de phase II (Étude 10040030) effectué dans 20 centres médicaux au Japon. C'est un essai à répartition aléatoire, mené en double insu pour comparer le TAS-102 à un placébo. Il porte sur 172 patients souffrant de cancer colorectal récurrent à un stade avancé, non résécable et réfractaire aux chimiothérapies standard d'au moins deux régimes contenant un mélange de fluoropyrimidine, d'irinotécan et d'oxaliplatine. Selon les résultats, le groupe à qui le TAS-102 a été administré a vu son taux de survie s'améliorer (durée médiane de survie globale : 9 mois contre 6,6 mois) et le risque de mortalité significativement réduire (HR : 0.56, p=0.0011). L'effet secondaire au médicament CTCAE de niveau 3 ou plus le plus fréquemment rapporté est la neutropénie. La diarrhée, la fatigue, la nausée et autres effets secondaires de niveau 3 n'ont pas dépassé les 10 %. Taiho Pharmaceutical mène actuellement un essai clinique mondial de phase III portant sur le TAS-102 sur une population similaire souffrant d'un cancer colorectal (RECOURSE
'/>"/>

SOURCE Taiho Pharmaceutical Co., Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
2. Jazz Pharmaceuticals Reports Full Year And Fourth Quarter 2012 Financial Results
3. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Cowen & Company 33rd Annual Health Care Conference In Boston On March 5, 2013
4. Global Pharmaceutical Industry Trends: Procurement Budgets Stay the Same, Marketing Budgets to Experience Slight Decrease
5. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2012 Financial Results Conference Call on Tuesday, March 19, 2013
6. Savara Pharmaceuticals Announces Formation of Clinical Advisory Board
7. Isis Pharmaceuticals Initiates Phase 2 Study Of ISIS-CRP Rx In Patients With Atrial Fibrillation
8. UBM Launches PharmaEvolution.com, an Online Peer-to-Peer Network for Pharmaceutical Industry Professionals
9. Alexza Pharmaceuticals Corporate Presentation to Be Webcast at Three Upcoming Investor Conferences
10. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Monday, March 4
11. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... Hospira, Inc. (NYSE: HSP ), a ... about the importance of extrapolation in bringing biosimilars to ... European Biosimilars Group conference in London ... of a pivotal white paper titled, "Why extrapolation ... Speaking at the EGA conference, Sumant ...
(Date:4/24/2015)... , April 24, 2015  Blueprint Medicines ... a selective and potent inhibitor of fibroblast growth ... in models of hepatocellular carcinoma (HCC) that are ... candidate, BLU-554 induced complete tumor regression in a ... FGFR4-activating ligand at the highest dose levels. These ...
(Date:4/23/2015)... April 23, 2015  Edwards Lifesciences Corporation (NYSE: EW ... valves and hemodynamic monitoring, today reported net income for ... $1.12 per diluted share.  Net income for the same ... per diluted share, and non-GAAP net income was $82.1 ... sales for the quarter ended March 31, 2015 increased 13.0 ...
Breaking Medicine Technology:Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 2Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 3Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 4Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 5Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 6Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 7Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 2Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 3Edwards Lifesciences Reports First Quarter Results 2Edwards Lifesciences Reports First Quarter Results 3Edwards Lifesciences Reports First Quarter Results 4Edwards Lifesciences Reports First Quarter Results 5Edwards Lifesciences Reports First Quarter Results 6Edwards Lifesciences Reports First Quarter Results 7Edwards Lifesciences Reports First Quarter Results 8Edwards Lifesciences Reports First Quarter Results 9Edwards Lifesciences Reports First Quarter Results 10Edwards Lifesciences Reports First Quarter Results 11Edwards Lifesciences Reports First Quarter Results 12Edwards Lifesciences Reports First Quarter Results 13Edwards Lifesciences Reports First Quarter Results 14Edwards Lifesciences Reports First Quarter Results 15Edwards Lifesciences Reports First Quarter Results 16
... 2011 Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, ... upcoming investor conferences in Paris.  Dr. Fernandes will present at ... CET, May 24, at the Hilton Arc de Triomphe.  Dr. ... at 3:00 p.m. CET, May 24, at the Paris Marriott ...
... May 18, 2011 Perrigo Company (Nasdaq: PRGO ... that it has received tentative approval from the U.S. Food ... Levocetirizine Solution, 2.5 mg/5ml, a generic version of UCB,s Xyzal® ... ANDA application for the generic that can entitle it to ...
Cached Medicine Technology:Cempra Pharmaceuticals to Present at Two Investor Conferences in Paris 2Perrigo's Partner Synthon Receives FDA Tentative Approval for Levocetirizine Solution - Generic Equivalent to Xyzal® Oral Solution 2Perrigo's Partner Synthon Receives FDA Tentative Approval for Levocetirizine Solution - Generic Equivalent to Xyzal® Oral Solution 3
(Date:4/25/2015)... 25, 2015 In the United States ... above needed treatment for an illicit drug ... Abuse and Mental Health Services Administration’s Survey on Drug ... alarming numbers are harrowing stories of men and women ... . David H. Kerr , founder and retired ...
(Date:4/25/2015)... NV (PRWEB) April 25, 2015 The ... is still eliciting the excitement of the public and ... into the months of May and June. From ... held their biannual tradition of "Special Prayers." More than ... had attended previous Special Prayers and have reported intense ...
(Date:4/25/2015)... April 25, 2015 The URO CENTER of ... has been chosen by the New York Academy of Medicine ... medicine in the field of Urology. , Dr. Ferdinand Valentine, ... speciality, Genito-Urinary diseases. He was a man of rare ... of urology. Not only did he devote his life ...
(Date:4/24/2015)... Bird B Gone, the leader in bird control products ... line of bird control solutions to address the growing threat ... Threaten Pacific, Central and Mississippi Farms , According to an ... of highly pathogenic avian flus in the Pacific, Central and ... wild birds enter poultry farms. The USDA urges farmers to ...
(Date:4/24/2015)... 2015 Ryadon is a leading manufacturer ... capabilities and services to complement any custom hardware requirements ... Program will be offered on all heavy duty drawer ... Receive 10% discount - Order 20+: Receive 20% discount ... Slides Products, Furniture ,Drawer ...
Breaking Medicine News(10 mins):Health News:New Book Features Powerful Stories of People Who Overcame Addiction 2Health News:New Book Features Powerful Stories of People Who Overcame Addiction 3Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 2Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 3Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 2Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 3Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 2Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 3Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 4Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 2Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 3
... disease through causing inflammation of the arteries. There is mounting evidence ... new study uncovers a link between the mouth and the heart ... Buffalo find that people with gum disease have higher than normal ... enter the circulation via the gums, and then trigger the liver ...
... way of treating tissue at the back of the mouth is ... 30 per cent of women have a problem with snoring - ... in the soft palate - the area of tissue at the ... tonsils, and the base of the tongue. Surgery that makes this ...
... disease also improves the paralysis experienced by stroke survivors.,Levodopa ... and this may help brain cells involved in controlling ... treatment in Parkinson's disease, but a new trial suggests ... ,// ,Researchers at the Bad Aibling Neurological ...
... Researchers at the University of Pittsburgh School of Medicine ... women's concerns about weight is the first treatment to ... for weight-concerned women assumed that the best approach to ... weight gain after they quit smoking. This study, as ...
... influence the risk of oesophagal cancer. ,A family in Liverpool, ... the genetic basis of cancer of the oesophagus. Twenty one ... five generations. The disease affects those who also have a ... researchers are studying 350 members of the extended Liverpool family. ...
... who eat the healthiest diets also eat a lot of ... Index (HEI) is a measure that US nutritionists have developed ... eating pattern rather than intake of specific nutrients. You get ... milk or meat, ten more possible points for dietary limitations ...
Cached Medicine News:Health News:Stop smoking and reduce weight 2
Mounted on a fully adjustable molded,headband with crown strap and comfort,cushions, the sturdy Halogen III Classic is,lightweight, comfortable and durable....
Mounted on a sturdy, molded headband,the Classic has a fully adjustable crown,strap and cushioning that adds to,your comfort....
... ICON DS Strep A is a qualitative ... from throat swabs. The ICON DS Strep A ... especially in rare and low positive colonization samples. ... format. With outstanding performance, ICON DS Strep A ...
... The Inverness Medical Ovulation Test Kits help ... five ovulation predictor sticks to help you predict ... The tests quickly and accurately detect the increase ... which normally occurs 24 to 48 hours before ...
Medicine Products: